The widely accepted approach for proving the efficacy and safety of novel medications is still the traditional “linear and sequential” clinical trial technique. However, poor patient selection, recruitment, retention, management issues, and insufficient patient monitoring etc. are partially responsible for the lengthening of studies and high trial failure rates. Artificial intelligence (AI) has the ability to reduce clinical cycle times by lowering the cost and burden of clinical development.
AI deployment requires proof of concept, qualified knowledge base, and model training. AI reduces the time it takes for life-saving drugs to reach the market by freeing up human workers’ time from repetitive tasks so they may focus on more specialized work, and directs future research by analysing past and present trial data. AI can shift focus from trial implementation to drug discovery, providing better medications for patients.
for more info https://www.novumprs.com/ai-in-clinical-trials-present-future/